Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZF2001 + tetravalent influenza virus lysis vaccine
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ZF2001 + tetravalent influenza virus lysis vaccine is a co-administration regimen or combination product consisting of the recombinant protein subunit COVID-19 vaccine ZF2001 (Zifivax) and a tetravalent inactivated split-virion influenza vaccine. ZF2001, developed by Anhui Zhifei Longcom, utilizes the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein produced in Chinese Hamster Ovary (CHO) cells and is adjuvanted with aluminum hydroxide. The tetravalent influenza component contains hemagglutinin from four seasonal influenza strains (typically A/H1N1, A/H3N2, and two B lineages). This combination is primarily studied to evaluate the safety and immunogenicity of simultaneous vaccination against both COVID-19 and seasonal influenza, aiming to simplify immunization schedules and improve compliance during overlapping outbreaks.
- Brand names
- Zifivax
- Other names
- recombinant novel coronavirus vaccine (CHO cell)tetravalent influenza virus lysis vaccinetetravalent influenza split vaccinerecombinant COVID-19 vaccine (CHO cell) combined with tetravalent influenza vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on ZF2001 + tetravalent influenza virus lysis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZF2001 + tetravalent influenza virus lysis vaccine.